21 October 2026
OpenAI buys Orchestra Bio to add drug-development agents to its life sciences unit
First reported
OpenAI, SiliconANGLE and 1 other ran this on , a day before the next source picked it up.
- OpenAI, the maker of ChatGPT, bought Orchestra Bio, a startup that builds AI agents to help drugmakers coordinate their development work.
- Orchestra's team and technology will join Rosalind, OpenAI's AI platform for life sciences research, which is used by Moderna and Novo Nordisk.
- OpenAI says developing a new drug in the US takes 10 to 15 years on average, and the agents aim to speed up tracking of trials and scheduling problems.
Our read
Earlier on this story
Written by Newskeryx from which newsletters covered this story and from our own archive.
Reported by The Decoder, SiliconANGLE, TechCrunch, OpenAI